Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2232 | Ivermectin + Doxycycline Wiki | 0.58 |
| drug2989 | Oral fluid swab Wiki | 0.58 |
| drug4639 | Venepuncture Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D008585 | Meningitis, Meningococcal NIH | 0.82 |
| D004165 | Diphtheria NIH | 0.58 |
| D014390 | Tuberculosis, Meningeal NIH | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0001287 | Meningitis HPO | 1.00 |
| HP:0002090 | Pneumonia HPO | 0.03 |
Navigate: Correlations HPO
There are 3 clinical trials
This is a pilot study to assess the feasibility of establishing a national sero-epidemiological survey in England in individuals aged 0-24 years, focusing on assessing humoral immunity against diphtheria, Group C invasive meningococcus and SARS-CoV-2. The investigators will recruit 2800 to 3500 individuals, divided into two groups: Group one (N= 2300): This will include all age groups (0-24years), with recruitment restricted by postcodes provided by Public Health England (PHE) to recruit a representative population for the region as assessed by the IMD (Index of Multiple Deprivation scores). Group two (N= up to 1200): This group has been added following additional funding to enhance the sample size in response to the COVID-19 pandemic. This will recruit 0-19 year olds and will not be restricted by post code sampling. Instead recruitment will be by public promotion within the normal recruiting regions for each site.
Description: Measure the representativeness of participants as compared to the census data for the study region.
Measure: Feasibility of developing an England based sero-epidemiological programme in 0-24 year olds Time: 11monthsDescription: Test serological markers of immunity for vaccine preventable diseases starting with diphtheria.
Measure: Feasibility of developing an England based sero epidemiological survey in 0-24 year olds Time: 11 monthsDescription: Test serological markers of immunity for vaccine preventable diseases including Invasive Meningococcal type C.
Measure: Feasibility of developing an England based sero epidemiological survey in 0-24 year olds Time: 11 monthsDescription: Test serological markers to determine the true number of infections with SARS-CoV-2 in the population.
Measure: Feasibility of developing an England based sero epidemiological survey in 0-24 year olds Time: 11 monthsDescription: Recruitment rate per month, recruitment rates as percentage of potential participants contacted
Measure: Recruitment rate Time: 11 MonthsDescription: Cost per sample obtained of 'disease specific correlates of protection/markers of immunity, e.g. Anti-Diphtheria Toxoid IgG concentrations and Capsular Group C meningococcal Serum bactericidal activity (SBA) titres and Serum IgG to SARS-CoV-2 antigens, including spike protein (as measured by ELISA and/or neutralising assay)
Measure: Cost Time: 12 monthsDescription: IgG to COVID-19 spike protein
Measure: To assess, in relevant age groups, antibody concentrations against infections and vaccine preventable diseases Time: 11 monthsDescription: A collection of anonymised sera from participants with appropriate consent and known demographic details and immunisation history. Serum IgG to SARS-CoV-2 antigens, including spike protein (as measured by ELISA and/or neutralising assay)
Measure: Sera collection Time: 11 monthsDescription: • Representativeness of participants sampled, in terms of the local population's ethnicity, community identity, migrant population and socioeconomic background in group 1 and group 2. Differences in immunological read outs PCR for SARS-CoV-2 on saliva samples this will be stored and processed at the end of the study. IgA to SARS-CoV-2 in saliva paired with serum samples.
Measure: Exploratory Time: 11 monthsDescription: • T cell responses to SARS-CoV-2 antigens including, but not limited to S, M and N proteins, as measured by techniques including, but not limited to ELISpot ICS Proliferation assay
Measure: Exploratory Time: 6 monthsDescription: • Antigen specific IgG and T cells against non-SARS-CoV-2 coronaviruses (e.g. NL62 and 229E)
Measure: Exploratory Time: 6 monthsAs Covid 19 manifestations that have been recently described, inflammatory manifestation have major impact in infectious disease lesions. Some of them are delayed and provide Post infectious inflammatory reaction (PIIR), they are challenging for diagnosis and for management. Clinician have to avoid unnecessary antibiotic thearapy and in if necessary have to give immunosuppressive therapy. Except for rheumatic disease for group A streptococcus (GAS) infections there are not stanrdized diagnostic criteria and therapeutic protocol, and PIIR have probably a suboptimal management. In this context the investigators aim to explore PIIR in the 3 most frequent bacterial invasive infection in France, by a retrospective monocentric study. The investigators include all children betwwen 2012 and 2018 hospitalized for infections by Streptococcus pneumoniae (SP), Neisseria meningitidis (NM), and GAS invasive infections.
Description: Describe the frequency PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection
Measure: Describe the frequency PIIRs Time: 1 dayDescription: Describe the characteristics PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection
Measure: Characteristics PIIRs following invasive pneumococcal, meningococcal, or group A Streptococcal infection Time: 1 dayDescription: Identified the predictors of PIIRs in order to find warning symptoms
Measure: Predictors of PIIRs Time: 1 dayTubercular meningitis occurs in around 10% of those with extrapulmonary tuberculosis and is a major cause of mortality and morbidity. Inspite of effective Anti-tubercular drugs, still around 30% of patients develop complications due to arachnoiditis such as spinal tubercular radiculomyelitis, optico-chiasmatic arachnoiditis, development of new tuberculomas after starting therapy etc. which are probably immune mediated inflammatory responses due to paradoxical reaction to ATT. The management of arachnoiditis is far from satisfactory. High dose methylprednisolone, intrathecal hyaluronic acid, thalidomide have been tried in small case series and case reports. However, the results have not been satisfactory. There are two published reports of cyclophosphamide usage in TBM related vasculitis and stroke The investigators tried cyclophosphamide in four patients after consent, and found remarkable improvement in all of them. (Under peer review) In order to test this hypothesis, a randomized controlled trial is needed.
Description: To compare the proportion of patients who attain functional independence (mRS-modified Rankin scale 0-2) 6 months after cyclophosphamide therapy for proliferative arachnoiditis refractory to corticosteroids and standard Anti-tubercular therapy in CNS tuberculosis to those who receive placebo.
Measure: Functional independece at 6 months Time: 6 monthsDescription: To compare the proportion of patients who attain independent ambulation 6 months after cyclophosphamide therapy for proliferative arachnoiditis refractory to corticosteroids and standard Anti-tubercular therapy in CNS tuberculosis to those who receive placebo.
Measure: Independent ambulation Time: 6 monthsDescription: To compare the proportion of patients improving from mRS ≥3 to mRS ≤2 six months post cyclophosphamide therapy
Measure: Improvement in modified Rankin scale Time: 6 monthsDescription: To compare the proportion of patients who attain atleast 2 points improvement on Snellen's chart in visual acuity 6 months after cyclophosphamide therapy for proliferative arachnoiditis refractory to corticosteroids and standard Anti-tubercular therapy in CNS tuberculosis to those who receive placebo.
Measure: Improvement in visual acuity (1) Time: 6 monthsDescription: To compare proportion of patients who attain atleast two point improvement on a semiquantitative visual acuity measurement in those who have visual acuity less than 1/60 on snellen's chart (finger counting at 1 m, hand movements at 1 m, perception of light, no perception of light considered as discrete points below 1/60 vision on standard Snellen's chart) 6 months after cyclophosphamide therapy
Measure: Improvement in visual acuity (2) Time: 6 monthsDescription: To compare proportion of patients improving from visual acuity of <3/60 in the better eye to 3/60 or more 6 months post cyclophosphamide therapy
Measure: Improvement in visual acuity (3) Time: 6 monthsDescription: To compare the proportion of patients who attain improvement in bladder/bowel function 6 months after cyclophosphamide therapy for proliferative arachnoiditis refractory to corticosteroids and standard Anti-tubercular therapy in CNS tuberculosis to those who receive placebo..
Measure: Improvement in sphincter function Time: 6 monthsDescription: Shift analysis pre-and 6 months post therapy in terms of change in mRS
Measure: Change in mRS Time: 6 monthsDescription: Comparing Global patient well being as assessed by SF-36 pre and 6 months post cyclophosphamide therapy
Measure: Patient well being Time: 6 monthsDescription: Occurrence of life threatening infections necessitating cessation of therapy upto 3 months post cyclophosphamide therapy
Measure: Life threatening infections Time: 3 monthsDescription: Occurrence of infections needing hospitalization or intravenous antibiotic/antiviral/anti-fungal therapy upto 3 months post cyclophosphamide therapy
Measure: Infections needing hospitalization Time: 3 monthsDescription: Flare up of underlying tuberculosis upto 3 months post cyclophosphamide therapy
Measure: Flare up of TB Time: 3 monthsDescription: Occurrence of Grade III cytopenias defined as per common terminology criteria for adverse events v 5.0 upto 6 weeks post cyclophosphamide therapy
Measure: Cytopenias Time: 6 weeksDescription: Grade III transaminitis as per CTCAE v 5.0 upto 6 weeks post cyclophosphamide therapy
Measure: Transaminitis Time: 6 weeksDescription: Occurrence of hemorrhagic cystitis upto 2 weeks post cyclophosphamide therapy
Measure: Hemorrhagic cystitis Time: 2 weeksDescription: Any other significant adverse effect
Measure: Adverse effects Time: 3 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports